Am J Health Syst Pharm. 2011;68(16):1506-1519. b These values are mean population values based on data from dabigatran doses ranging from 10 to 400 mg given as single and multiple doses.

In March 2008, the European Commission granted marketing authorization for dabigatran etexilate (Pradaxa; Boehringer Ingelheim), a direct thrombin inhibitor, for the prevention of venous ...

All dosages should be adjusted in patients with reduced renal function. Dabigatran is currently being investigated for several thromboembolic disorders. It was approved by the Food and Drug ...